Introduction
Exciting presentations of new results, important updates of seminal trials, and expert perspectives were featured at the 2010 Genitourinary Cancers Symposium held in San Francisco, California in March. The co-sponsors for the meeting were the Society of Surgical Urology, the American Society of Clinical Oncology, and the American Society for Radiation Oncology. This newsletter highlights reports of interest for clinicians caring for patients with genitourinary (GU) cancers.
Featured Content
• Prostate Cancer (PC)
• Renal Cell Carcinoma (RCC)
• Bladder Cancer
Editors
Daniel P. Petrylak, MD, bio | Brian I. Rini, MD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours |
Release date: April 7, 2010 | Expiration date: April 6, 2011
Statement of Need
Advances in genitourinary cancers have resulted from decades of well-designed clinical trials and new insights into the biology as well as shifts in epidemiology, increasing development of and access to new agents, and rapid advances in diagnostic and therapeutic technologies. The management of genitourinary cancers in recent years has involved increasingly complex, combined-modality treatment approaches. Advances in treatment strategies have affected all the approaches used in genitourinary cancers: radiation therapy, chemotherapy, targeted agents, and surgery and supports a best practices model of multidisciplinary team involvement. Numerous ongoing trials are assessing the benefits of these and other novel agents, and as such, it is imperative that physicians and allied healthcare professionals (including nurses, nutritionists, and pharmacists) treating patients with genitourinary cancers be informed of the results of these trials to facilitate optimal management of genitourinary cancers. This newsletter will highlight areas of new knowledge from the 2010 Genitourinary Cancers Symposium, a meeting specially designed for the education and presentation of new data in genitourinary cancers.
Target Audience
The target audience for this program includes medical, surgical, and radiation oncologists, as well as allied oncology healthcare professionals who treat genitourinary cancers.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Describe the design and results of studies on treatment of genitourinary cancers presented at the 2010 Genitourinary Cancers Symposium
- Interpret study results in light of current standard of care of genitourinary cancers
- Outline recent information on risk factors for, prevention of, and management of serious treatment-related side effects in genitourinary cancers
- Incorporate individual patient parameters and toxicity considerations in selection of treatment for genitourinary cancers
|
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| PHARMACIST CONTINUING EDUCATION |
 |
Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UAN 0199-0000-10-002-H01-P). |
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period April 7, 2010 through April 6, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings. |
ACKNOWLEDGEMENT
The editors wish to thank Lea Ann Hansen, PharmD, BCOP, a paid employee of ECG, for assistance in writing this document.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from AstraZeneca, Dendreon Corporation, Genentech BioOncology, and sanofi-aventis Group.
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Daniel P. Petrylak, MD
Grants/Research Support
Celgene Corporation, Dendreon Corporation, GlaxoSmithKline, ImClone Systems, Pfizer Inc., Progenics, sanofi-aventis Group
Consultant Fees
AstraZeneca, Celgene Corporation, Dendreon Corporation, ImClone Systems, Millennium Pharmaceuticals, Inc., Pfizer Inc., Progenics, sanofi-aventis Group
Board Member
Prostate Conditions Education Council
Brian I. Rini, MD
Grants/Research Support
Pfizer Inc.
Consultant Fees
AVEO Pharmaceuticals, Inc., Genentech, Inc., Novartis, Pfizer Inc.
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE | Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net
|
